Caris Life Sciences Inc CAI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
-
Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing
-
Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test
-
Caris Life Sciences Announces Dual Listing on NYSE Texas
-
Caris Life Sciences Announces Share Repurchase Program
-
Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing
-
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek
-
Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels
Trading Information
- Previous Close Price
- $17.46
- Day Range
- $16.39–17.85
- 52-Week Range
- $14.19–42.50
- Bid/Ask
- $16.40 / $17.30
- Shares Outstanding
- 282.68M
- Market Cap
- $4.66B
- Volume/Avg
- 4M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 26.79
- Price/Sales
- 3.35
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,846
Valuation
|
Metric
|
CAI
|
|---|---|
Price/Earnings (Normalized) | 26.79 |
Price/Book Value | 8.32 |
Price/Sales | 3.35 |
Price/Cash Flow | 16.39 |
Price/Earnings
CAI
Financial Strength
|
Metric
|
CAI
|
|---|---|
Quick Ratio | 6.35 |
Current Ratio | 7.05 |
Interest Coverage | 1.19 |
Quick Ratio
CAI
Profitability
|
Metric
|
CAI
|
|---|---|
Return on Assets (Normalized) | 13.46% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 45.68% |
Return on Assets
CAI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@r>!^> | LOCK|<sq>F | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^$F@^X@ | LOCK|Yz&> | $70B | |||
| argenx SE ADR
ARGX
| LOCK|jQ%hT?? | LOCK|lCb | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|pg$mjr | LOCK|R<Bnx | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|fq!@jw | LOCK|?# | $37B | |||
| Moderna Inc
MRNA
| LOCK|QBfmGZq | LOCK|H^ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#&F@!B> | LOCK|RQ!hH | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|%@#jwM@ | LOCK|fR | $23B | |||
| Incyte Corp
INCY
| LOCK|B@%$h!y | LOCK|#l? | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|@bBTjHB | LOCK|!Q | $16B |
United States